Can Prestige Biopharma turn HD204 Phase 3 data into a credible Avastin biosimilar launch?
Prestige Biopharma reported positive HD204 Phase 3 data in NSCLC. Read what the bevacizumab biosimilar result could change next.
Pillar Biosciences launches rapid AML sequencing panel while Creatv Bio liquid biopsy enters colorectal cancer trial biomarker role
Pillar Biosciences launches rapid AML sequencing panel as Creatv Bio liquid biopsy enters colorectal cancer trial. Explore what these tools mean for oncology research.
Merck strengthens its women’s oncology position with KEYNOTE-B96 overall survival results
KEYNOTE-B96 shows overall survival gains for pembrolizumab in platinum-resistant ovarian cancer. Find out why this trial could reshape treatment strategy.
Lilly’s sofetabart mipitecan gets FDA Breakthrough Therapy designation for ovarian cancer
Eli Lilly and Company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational antibody-drug conjugate, sofetabart mipitecan, also known as LY4170156. The designation applies to adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior treatment with bevacizumab and mirvetuximab soravtansine. The novel […]